OBJECTIVE: During the follow-up of a group of patients with active tuberculosis, the predictive potential of several antibody-based assays was evaluated in monitoring treatment efficacy. DESIGN: Eleven patients with bacteriologically documented pulmonary tuberculosis and two patients with tuberculosis pleurisy were studied over a period of 6 months, from the day before treatment to its completion. The kinetics of the humoral response to Mycobacterium tuberculosis was determined by the number of specific circulating antibody secreting cells (ASC) (ELISPOT assay), as well as the titres of specific circulating antibody and specific antibody present in circulating immune complexes (quantitative ELISA). RESULTS: Follow-up ELISPOT assays, performed after initiation of tuberculosis therapy showed a rapid increase of ASC, during the first week, followed by rapid 3-10 fold decline of ASC in 12 of 13 patients tested. This decline occurred more rapidly than the mycobacterial culture conversion. In contrast, follow-up of ELISA assays did not give relevant information in assessing the outcome of treatment. CONCLUSION: In comparison with direct detection of tubercle bacilli in sputum samples, the rapid clearance of specific circulating ASC occurring early on after the onset of therapy could suggest a potential usefulness of ELISPOT in monitoring therapeutic response.
OBJECTIVE: During the follow-up of a group of patients with active tuberculosis, the predictive potential of several antibody-based assays was evaluated in monitoring treatment efficacy. DESIGN: Eleven patients with bacteriologically documented pulmonary tuberculosis and two patients with tuberculosis pleurisy were studied over a period of 6 months, from the day before treatment to its completion. The kinetics of the humoral response to Mycobacterium tuberculosis was determined by the number of specific circulating antibody secreting cells (ASC) (ELISPOT assay), as well as the titres of specific circulating antibody and specific antibody present in circulating immune complexes (quantitative ELISA). RESULTS: Follow-up ELISPOT assays, performed after initiation of tuberculosis therapy showed a rapid increase of ASC, during the first week, followed by rapid 3-10 fold decline of ASC in 12 of 13 patients tested. This decline occurred more rapidly than the mycobacterial culture conversion. In contrast, follow-up of ELISA assays did not give relevant information in assessing the outcome of treatment. CONCLUSION: In comparison with direct detection of tubercle bacilli in sputum samples, the rapid clearance of specific circulating ASC occurring early on after the onset of therapy could suggest a potential usefulness of ELISPOT in monitoring therapeutic response.
Authors: C P Landowski; H P Godfrey; S I Bentley-Hibbert; X Liu; Z Huang; R Sepulveda; K Huygen; M L Gennaro; F H Moy; S A Lesley; M Haak-Frendscho Journal: J Clin Microbiol Date: 2001-07 Impact factor: 5.948
Authors: Rubhana Raqib; S M Mostafa Kamal; M Jubayer Rahman; Zeaur Rahim; Sayera Banu; Pradip K Bardhan; Fahima Chowdhury; Gul Ara; K Zaman; Robert F Breiman; Jan Andersson; David A Sack Journal: Clin Diagn Lab Immunol Date: 2004-11
Authors: Lenka M Pereira Arias-Bouda; Sjoukje Kuijper; Anouk Van der Werf; Lan N Nguyen; Henk M Jansen; Arend H J Kolk Journal: Clin Diagn Lab Immunol Date: 2003-07
Authors: Alice L den Hertog; María Montero-Martín; Rachel L Saunders; Matthew Blakiston; Sandra Menting; Jeevan B Sherchand; Lovett Lawson; Olanrewaju Oladimeji; Saddiq T Abdurrahman; Luis E Cuevas; Richard M Anthony Journal: PLoS One Date: 2015-06-26 Impact factor: 3.240
Authors: Margaretha Sariko; Caitlin Anderson; Buliga S Mujaga; Jean Gratz; Stellah G Mpagama; Scott Heysell; Gibson Kibiki; Blandina Mmbaga; Eric Houpt; Tania Thomas Journal: PLoS One Date: 2017-01-13 Impact factor: 3.240